Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future therapy for hereditary angioedema.

Bruce L Zuraw1

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. zuraw@scripps.edu

Clinical Immunology (Orlando, Fla.)
|December 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary angioedema and post traumatic stress disorder: a reciprocal relationship?

Orphanet journal of rare diseases·2026
Same author

Arerugi = [Allergy]·2026
Same author

Incriminating the inotrope: Dobutamine, eosinophilia, and myocarditis.

The journal of allergy and clinical immunology. Global·2026
Same author

Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study.

Advances in therapy·2025
Same author

Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United States.

Allergy and asthma proceedings·2025

Hereditary angioedema (HAE) is a serious genetic disorder causing severe swelling attacks. New treatments are emerging to manage acute HAE attacks and prevent future occurrences.

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Hereditary angioedema (HAE) is an autosomal dominant disorder.
  • Characterized by recurrent, potentially fatal angioedema attacks lasting 3+ days.
  • Attacks begin in childhood and persist throughout life, leading to significant morbidity and mortality.

Purpose of the Study:

  • To review current and future therapeutic options for Hereditary Angioedema (HAE).
  • To discuss strategies for managing acute HAE attacks and preventing future occurrences.
  • To highlight the unmet need for effective HAE therapies in the United States.

Main Methods:

  • Review of existing literature on HAE pathophysiology and treatment.
  • Analysis of clinical trial data for emerging HAE therapies.

Related Experiment Videos

  • Discussion of current treatment landscape and anticipated advancements.

    • Main Results:

    • Several novel molecules show promise for treating acute HAE attacks.
    • These new therapies are expected to become available in the United States soon.
    • Effective management requires both acute attack treatment and preventative strategies.

    Conclusions:

    • Minimizing HAE morbidity and mortality necessitates effective acute attack management and prevention.
    • The therapeutic landscape for HAE is evolving, with promising new options on the horizon.
    • Patients with HAE face a significant unmet need for timely and effective treatment options.